APA (7th ed.) Citation

RS, J., PS, S., PH, B., A, d. l. P., PP, C., I, S., . . . RJ, S. (2022). Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. Clinical medicine insights. Circulatory, respiratory and pulmonary medicine, 16, 11795484221119316. https://doi.org/10.1177/11795484221119316

Chicago Style (17th ed.) Citation

RS, Jones, Smith PS, Berg PH, de la Peña A, Cook PP, Shawa I, Kioussopoulos KM, Hu Y, and Schott RJ. "Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19." Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine 16 (2022): 11795484221119316. https://doi.org/10.1177/11795484221119316.

MLA (9th ed.) Citation

RS, Jones, et al. "Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19." Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine, vol. 16, 2022, p. 11795484221119316, https://doi.org/10.1177/11795484221119316.